BIOVIE Business Summary

BioVie Inc. (BIVI) is a clinical-stage biopharmaceutical company that operates as a pre-revenue entity, generating capital primarily through public equity offerings and strategic financing rather than commercial product sales. The company operates in a single business segment focused on the development of novel therapies for neurodegenerative disorders and advanced liver disease. Its pipeline is anchored by two lead candidates: bezisterim (NE3107), an oral small molecule targeting neuroinflammation and insulin resistance in Alzheimer’s and Parkinson’s diseases, and BIV201, a continuous-infusion terlipressin formulation for liver cirrhosis complications such as ascites. BioVie competes in a high-stakes market against players like INmune Bio, SAGE Therapeutics, Pliant Therapeutics, and Madrigal Pharmaceuticals, positioning itself as a specialized developer of anti-inflammatory epigenetic modulators for orphan and age-related indications. The leadership team is headed by President and CEO Cuong Viet Do, a former Senior Partner at McKinsey & Company and former Chief Strategy Officer at Merck, who provides the firm with deep global pharmaceutical and strategic pedigree. Clinical development is overseen by Executive Vice President of R&D and Chief Medical Officer Joseph M. Palumbo, MD, a veteran of Mitsubishi Tanabe and Johnson & Johnson, alongside Chief Financial Officer Wendy Kim. Founded in 2013 with early strategic backing from Terren Peizer (Acuitas Group Holdings), the company is governed by a board chaired by James Lang. Notable institutional support includes positions from Vanguard Group, Diametric Capital, and Prelude Capital Management, though the company remains heavily reliant on its Corporate Advisory Board, which includes high-profile figures such as Neuralink co-founder Tim Gardner and Cedars-Sinai’s Dr. Zaldy Tan.